SAN DIEGO, April 11, 2011 – Polaris Group (Polaris) announced today that data from preclinical studies of ADI‑PEG 20, the Company’s pegylated arginine deiminase therapeutic, is synergistic with hydroxychloroquine (ChQ) in a human pancreatic cancer cell line and with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human melanoma cell lines. Both ChQ and TRAIL are known inhibitors of autophagy.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2011-04-11 19:55:142018-02-19 19:56:44Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI‑PEG 20 Works Synergistically with Inhibitors of Autophagy
SAN DIEGO, April 7, 2011 – Polaris Group (Polaris) announced today that data from preclinical studies suggest ADI‑PEG 20, the Company’s pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2011-04-07 19:56:532018-02-19 19:58:04Transcriptional Silencing of ASS1 suggests the Potential Use of ADI‑PEG 20 to Treat AML, Glioblastoma and Bladder Cancer
SAN DIEGO, March 31, 2011 — Polaris Group (Polaris) today announced that the U.S. Food & Drug Administration (FDA) has approved the company’s Special Protocol Assessment (SPA) for a Phase 3 clinical trial of pegylated arginine deiminase (ADI‑PEG 20) in patients with advanced hepatocellular carcinoma (HCC).
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2011-03-31 19:58:182018-02-19 19:59:19FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Group’s Cancer Therapeutic, ADI‑PEG 20, in the Treatment of Hepatocellular Carcinoma
SAN DIEGO, March 18, 2011 — Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI‑PEG 20 (pegylated arginine deiminase), the company’s novel enzyme-based treatment for malignant mesothelioma. This randomized trial, called “ADAM” (Arginine Deiminase And Mesothelioma),…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2011-03-18 19:59:412018-02-19 20:00:48Polaris Enrolls First Patient in Phase 2 Clinical Trial of ADI‑PEG 20 for the Treatment of Malignant Mesothelioma
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2011-03-15 20:01:022018-02-19 20:01:55Polaris Group Appoints Robert E. Hoffman as Chief Financial Officer
NEW YORK and SAN DIEGO, February 14, 2011 — Polaris Group (Polaris) and The Ludwig Institute for Cancer Research (LICR) today announced the enrollment of the first patient in a Phase 2 clinical trial evaluating ADI‑PEG 20…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2011-02-11 20:02:092018-02-19 20:03:06Polaris Group and the Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI‑PEG 20, in Patients with Small Cell Lung Cancer
Physicians attending the annual meeting of the American Society of Clinical Oncology (ASCO) presented evidence that pegylated arginine deiminase (ADI‑PEG 20), a novel anticancer drug that targets ASS(-) tumors, and which is being developed and manufactured by Polaris Group, was effective in inhibiting the growth of metastatic melanoma cells.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2010-06-07 20:03:092018-02-19 20:04:54Phase II Clinical Trial Results of “ADI‑PEG 20” Show Efficacy in Human Metastatic Melanoma Deficient in a Key Metabolic Enzyme, and in Lymphomas in Preclinical Studies
Polaris Group scientists and university collaborators reported at the American Association for Cancer Research (AACR), that a number of different cancers have a deficiency in a specific enzyme, argininosuccinate synthetase (ASS), which allows pegylated arginine deiminase (ADI‑PEG 20) to inhibit cancer cell growth.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2010-04-22 20:05:092018-02-19 20:06:47Multiple Tumors Deficient in a Specific Enzyme Are Sensitive to a New Drug “ADI‑PEG 20”
Dr. Niramol Savaraj, Polaris collaborator and one of the principal investigators of the ongoing Phase 2 study of ADI‑PEG 20 in metastatic melanoma, will be presenting a poster at American Association for Cancer Research’s (AACR) 100th Annual Meeting, April 2009.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2009-04-17 20:06:512018-02-19 20:08:26Polaris Collaborator to Present Research into ADI‑PEG 20’s Mechanism of Action at AACR 2009
Polaris, in collaboration with the Ludwig Institute for Cancer Research (LICR), held an Advisory Panel Meeting on January 15, 2009 in San Francisco. The meeting was held to discuss the design of a pivotal Phase 3 clinical trial of ADI‑PEG 20 in patients with hepatocellular carcinoma.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2009-01-16 20:08:292018-02-19 20:09:59Advisory Panel Meeting Held in San Francisco: Plans for Phase 3 Trial of ADI‑PEG 20 in HCC Patients Discussed